Literature DB >> 2776455

BOOMER, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis.

D W Bourne1.   

Abstract

BOOMER is an improved version of an earlier non-linear regression program, MULTI-FORTE. Rather than the user writing a FORTRAN subroutine, models are defined by means of the parameters which make up the model. Models based on differential equations are specified by means of zero-order, first-order, or Michaelis-Menten-type rate constants. Doses (in units of mass) are translated into the usually observed concentration units by a reciprocal volume parameter. Integrated equation models are specified in terms of baseline terms, exponential terms, or the emax function with slope term as described by the Hill equation. Time points can be specified as parameters to specify dose times, infusion start/stop times, or lag times. With careful selection of parameters quite complex models can be specified. The user has a choice of differential equation solvers and fitting algorithms.

Entities:  

Mesh:

Year:  1989        PMID: 2776455     DOI: 10.1016/0169-2607(89)90129-6

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  14 in total

1.  Accelerated Blood Clearance of Antibodies by Nanosized Click Antidotes.

Authors:  Weston J Smith; Guankui Wang; Hanmant Gaikwad; Vivian P Vu; Ernest Groman; David W A Bourne; Dmitri Simberg
Journal:  ACS Nano       Date:  2018-12-05       Impact factor: 15.881

2.  Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Authors:  Rajendra S Kadam; David W A Bourne; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-04-12       Impact factor: 3.922

3.  PAVA: physiological and anatomical visual analytics for mapping of tissue-specific concentration and time-course data.

Authors:  Michael-Rock Goldsmith; Thomas R Transue; Daniel T Chang; Rogelio Tornero-Velez; Michael S Breen; Curtis C Dary
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-05-22       Impact factor: 2.745

4.  Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.

Authors:  Panos G Georgopoulos; Alan F Sasso; Sastry S Isukapalli; Paul J Lioy; Daniel A Vallero; Miles Okino; Larry Reiter
Journal:  J Expo Sci Environ Epidemiol       Date:  2008-03-26       Impact factor: 5.563

5.  In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M Manduru; L B Mihm; R L White; L V Friedrich; P A Flume; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; F Ma; Y Wang; C Smith
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

7.  Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

Authors:  Rheal A Towner; David L Gillespie; Andrea Schwager; Debra G Saunders; Nataliya Smith; Charity E Njoku; Richard S Krysiak; Chelsea Larabee; Henna Iqbal; Robert A Floyd; David W A Bourne; Osama Abdullah; Edward W Hsu; Randy L Jensen
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

8.  Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; J Wang
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

9.  Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.

Authors:  C M Paap; M C Nahata; M A Mentser; J D Mahan; S K Puri; J W Hubbard
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent.

Authors:  C L Chen; S Sangiah; D W Bourne; J D Roder; H Chen; F K Alavi; C R Clarke; G L Garrison; K D Berlin; K M Couch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.